Literature DB >> 23246551

The field effectiveness of routine and emergency vaccination with an inactivated vaccine against foot and mouth disease.

E Elnekave1, Y Li, L Zamir, B Even-Tov, P Hamblin, B Gelman, J Hammond, E Klement.   

Abstract

High potency, inactivated foot and mouth disease (FMD) vaccines may be used in non endemic countries for emergency vaccination during outbreaks in order to prevent virus spread. In endemic countries either standard or high potency vaccines are used for routine vaccination. Despite their wide use there is a shortage of data on the field effectiveness of inactivated FMD vaccines. Epidemics of FMD caused by viruses of serotype O occur frequently in Israel, where a high potency (≥6PD(50)) vaccine is used for both routine and emergency vaccination. We investigated an outbreak of FMD caused by a virus of serotype O, which took place during 2011 in a feedlot and an adjacent dairy herd. Post outbreak testing of antibodies against non-structural protein demonstrated that infection occurred in 96% of the calves that received two doses of vaccine at least three months prior to the outbreak and more than 50% showed clinical signs consistent with FMD. Replacement heifers that had been vaccinated 3-5 times with the last vaccination administered 7 months prior to the outbreak were all infected and 18% showed clinical signs. Testing of cattle sera of the same vaccination status as the affected cattle demonstrated low neutralizing antibody (NA) titers against the field virus strain and an r(1) value of 0.37 compared to the vaccine strain. In contrast, cattle vaccinated only once but up to two weeks before the outbreak, were almost all protected from clinical disease and to a lesser extent, protected from FMD virus infection, despite low NA titers. We conclude that emergency vaccination was highly effective due to a mechanism not associated with NA, whereas routine vaccination with the same vaccine formulation provided only limited protection due to poor longevity of the elicited immunity and low matching with the field strain (despite an r(1) higher than 0.3).
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23246551     DOI: 10.1016/j.vaccine.2012.12.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Association of the time that elapsed from last vaccination with protective effectiveness against foot-and-mouth disease in small ruminants.

Authors:  Ehud Elnekave; Boris Even-Tov; Boris Gelman; Beni Sharir; Eyal Klement
Journal:  J Vet Sci       Date:  2014-10-08       Impact factor: 1.672

2.  Supplementation of dietary germanium biotite enhances induction of the immune responses by foot-and-mouth disease vaccine in cattle.

Authors:  Myunghwan Jung; Min-Kyoung Shin; Seung-Bin Cha; Seung Won Shin; Anna Yoo; Won-Jung Lee; Hong-Tae Park; Jong-Hyeon Park; Byounghan Kim; Yeon-Kwon Jung; Han Sang Yoo
Journal:  BMC Vet Res       Date:  2014-08-12       Impact factor: 2.741

Review 3.  Foot-and-Mouth Disease Impact on Smallholders - What Do We Know, What Don't We Know and How Can We Find Out More?

Authors:  T J D Knight-Jones; M McLaws; J Rushton
Journal:  Transbound Emerg Dis       Date:  2016-05-11       Impact factor: 5.005

4.  Risk factors for recurrence of FMD outbreaks in Iran: a case-control study in a highly endemic area.

Authors:  Kayhan Ilbeigi; Saied Bokaie; Sina Aghasharif; Ricardo J Soares Magalhães; Mohamad Rashtibaf
Journal:  BMC Vet Res       Date:  2018-08-29       Impact factor: 2.741

5.  The epidemiology of foot-and-mouth disease outbreaks and its history in Iraq.

Authors:  Karima Akool Al-Salihi
Journal:  Vet World       Date:  2019-05-25

6.  Antigenic properties and virulence of foot-and-mouth disease virus rescued from full-length cDNA clone of serotype O, typical vaccine strain.

Authors:  Rae-Hyung Kim; Jia-Qi Chu; Jeong-Nam Park; Seo-Yong Lee; Yeo-Joo Lee; Mi-Kyeong Ko; Ji-Hyeon Hwang; Kwang-Nyeong Lee; Su-Mi Kim; Dongseob Tark; Young-Joon Ko; Hyang-Sim Lee; Min-Goo Seo; Min-Eun Park; Byounghan Kim; Jong-Hyeon Park
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

7.  Evaluation of a polyvalent foot-and-mouth disease virus vaccine containing A Saudi-95 against field challenge on large-scale dairy farms in Saudi Arabia with the emerging A/ASIA/G-VII viral lineage.

Authors:  Nicholas A Lyons; Anna B Ludi; Ginette Wilsden; Pip Hamblin; Ibrahim Ahmed Qasim; Simon Gubbins; Donald P King
Journal:  Vaccine       Date:  2017-11-03       Impact factor: 3.641

8.  Spatial and temporal risk as drivers for adoption of foot and mouth disease vaccination.

Authors:  Ashley F Railey; Tiziana Lembo; Guy H Palmer; Gabriel M Shirima; Thomas L Marsh
Journal:  Vaccine       Date:  2018-07-06       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.